Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences
September 25 2018 - 08:00AM
Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that Nassim
Usman, Ph.D., president and chief executive officer
of Catalyst Biosciences, will present at the 2018 Cantor
Fitzgerald Global Healthcare conference, being held on Oct. 1-3,
2018 at the InterContinental New York Barclay Hotel in New York
City, and the Ladenburg Thalmann 4th Annual Healthcare
Conference, being held on Oct. 2, 2018 at the Sofitel New York in
New York City.
Cantor Fitzgerald Global Healthcare Conference Presentation
Details |
Date/Time: |
Monday, Oct. 1, 2018
from 2:55 - 3:25 p.m. EDT |
Location: |
InterContinental New
York Barclay Hotel |
|
Track 5 - Grand
Ballroom 2 |
Webcast
Link: |
http://wsw.com/webcast/cantor7/cbio/ |
|
|
Ladenburg Thalmann Healthcare Conference Presentation
Details |
Date/Time: |
Tuesday, Oct. 2, 2018
from 10:30 - 10:55 a.m. EDT |
Location: |
Sofitel New York |
|
Track 1 -
Trocadero |
A copy of the presentation materials can be accessed by visiting
the Events and Presentations section of the Catalyst website after
the presentations conclude. Archived presentation webcasts can be
accessed for 90 days.
About Catalyst Biosciences Catalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statement of
historical facts (including, but not limited to, statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates”) are forward-looking statements. Actual
results or events could differ materially from the plans,
intentions, expectations and projections disclosed in the
forward-looking statements. Various important factors could cause
actual results or events to differ materially from the
forward-looking statements that the Company makes, including, but
not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, that human trials will not
replicate the results from animal studies, that potential adverse
effects may arise from the testing or use of the Company’s
products, including the generation of antibodies, the risk that
costs required to develop or manufacture the Company’s products
will be higher than anticipated, competition and other factors that
affect our ability to establish collaborations on commercially
reasonable terms and other risks described in the “Risk Factors”
section of the Company’s Annual Report on Form 10-K for the year
ended December 31, 2016 and the Company’s Quarterly Reports on Form
10-Q for the quarters ended March 31, 2017, June 30, 2017, and
September 30, 2017 along with other filings with the Securities and
Exchange Commission. The Company does not assume any obligation to
update any forward-looking statements, except as required by
law.
ContactsInvestors:
Fletcher Payne,
CFO
Catalyst Biosciences,
Inc.
1.650.871.0761
investors@catbio.com
Media: Josephine Belluardo, Ph.D. LifeSci
Public Relations 1.646.751.4361 jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2023 to Mar 2024